在具有适应性丰富的两阶段生物标志物分层试验中的最佳性考虑
1Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Statistics in medicine
|November 17, 2025
概括
这项研究优化了针对性治疗的两阶段临床试验设计. 它为临时分析时间和样本大小调整提供了建议,当生物标志物负子组因徒劳而停止时.
科学领域:
- 临床试验方法论 临床试验方法论
- 生物统计学 生物统计学
- 药物基因组学 药物基因组学
背景情况:
- 生物标志物分层试验对于个性化医学至关重要,在特定的患者亚组中测试治疗方法.
- 有效的试验设计对于优化资源分配和患者招生至关重要.
研究的目的:
- 为生物标志物分层试验开发最佳的两阶段设计.
- 提供关于中间分析,徒劳性停止和样本大小调整的指导.
主要方法:
- 利用最佳性标准来推导两阶段试验设计.
- 调查了临时分析时间,徒劳边界和α分配.
- 确定生物标志物阳性子组的第二阶段样本大小,在生物标志物阴性子组中无效.
主要成果:
- 确定了双阶段生物标记物分层设计的最佳参数.
- 提供了临时分析和徒劳停止规则的建议.
- 根据中间结果重新分配样本大小的既定方法.
结论:
- 提出的方法提高了生物标志物分层临床试验的效率.
- 为设计和进行适应性试验提供了实际指导,以PrecISE喘试验为例.
更多相关视频
相关概念视频
Comparing the Survival Analysis of Two or More Groups
541
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
541
Assumptions of Survival Analysis
388
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
388
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
387
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
387
Bioavailability Study Design: Healthy Subjects Versus Patients
136
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
136
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
166
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
166
Kaplan-Meier Approach
541
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
541


